Amna Kamil Leads Systematic Review on Factor Xa Inhibitors for Cancer-Associated VTE
Amna Kamil, MS5 at JSMU (Jinnah Sindh Medical University) posted on LinkedIn:
”Publication Alert
Alhamdulillah
Thrilled to announce that my first Systematic Review and Meta-analysis has been published as First Author in Clinical and Applied Thrombosis/Hemostasis (SAGE Journals)
Why this research matters:
Cancer patients face a much higher risk of developing venous thromboembolism (VTE) – a major cause of morbidity and mortality. Traditional anticoagulants (like LMWH or VKAs) have limitations, leading to growing interest in Factor Xa inhibitors (DOACs such as apixaban and rivaroxaban).
What we found:
Factor Xa inhibitors significantly reduced the risk of VTE compared to placebo.
However, they were also linked to a higher risk of major bleeding.
The balance between benefit and risk highlights the importance of individualized patient selection and the need for further large-scale trials.
This work contributes to ongoing discussions on optimizing thromboprophylaxis in high-risk cancer patients, aiming for safer and more effective clinical decision-making.
This marks a special milestone in my research journey. Grateful to my incredible co-authors and mentors for their constant support and teamwork throughout this process.”
Read the full article here.
Title: “Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis”
Authors: Amna Kamil, Sandhiya Prem Kumar, Rumaisa Zulfiqar, Eiman Araib, Bibi Samia Khan, Muhammad Saad Khan, Muhammad Mohsin Khan, Umaimah Naeem, Aminath Waafira
Stay updated with Hemostasis Today.
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
-
Jan 16, 2026, 04:51Higher-Dose Clotting Factor Prophylaxis Does Not Reduce Postpartum Hemorrhage in Women with von Willebrand Disease
-
Jan 16, 2026, 04:48Reza Shojaei on Plasma Donation as Life-Changing Medicine in Motion
-
Jan 16, 2026, 04:11Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
-
Jan 16, 2026, 04:11Why is DVT More Common In the Left Leg? Dr Raheel Moazzam’s New Study Gives Answers!